Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial
Status:
Terminated
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
Full Title: A Randomized Controlled Trial of Procrit for the Prevention of Acute Renal
Failure in Patients Receiving Intravenous Contrast
Primary Objective: To evaluate the efficacy of a one-time dose of intravenous erythropoietin
administration in the prevention or attenuation of contrast-induced acute renal failure.
Secondary Objectives: To evaluate serum and urinary markers of renal injury, including KIM-1,
BMP-7, and TGF-b, along with other biomarkers, in subjects receiving intravenous contrast and
correlate their expression with clinical outcomes
Study Design: Prospective, multi-centered, randomized, double blind, placebo controlled trial
of a one-time dose of EPO. Subjects will be followed for seven days or until hospital
discharge, whichever is longer. Total estimated study duration 3 years.